# Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization

> **NCT03942601** · PHASE2 · TERMINATED · sponsor: **Mercator MedSystems, Inc.** · enrollment: 10 (actual)

## Conditions studied

- Peripheral Arterial Disease

## Interventions

- **DRUG:** Temsirolimus
- **DRUG:** Temsirolimus and dexamethasone sodium phosphate

## Key facts

- **NCT ID:** NCT03942601
- **Lead sponsor:** Mercator MedSystems, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-10-01
- **Primary completion:** 2021-04-30
- **Final completion:** 2021-04-30
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Halted due to pandemic.
- **Last updated:** 2024-07-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942601, "Temsirolimus Alone or Paired With Dexamethasone Delivered to the Adventitia to eNhance Clinical Efficacy After Femoropopliteal Revascularization". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03942601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*